Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
NCT04979611Phase 1Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2020
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium-68-DOTA-exendin-4 in insulinoma, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Standardized Uptake Value at 1 hour. Status: unknown.
02
Drugs
gallium-68-DOTA-exendin-4
03
Conditions
insulinoma
Beyond the preview
Go deeper on NCT04979611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979611.